Fischer Medical Ventures DuPont analysis

·Pharma & HealthChart ›
ProfitabilityGrowthCreditLiquidityWorking capitalDividend yieldDuPontCAGR
Per cent unless marked ×
Tap a line for its trendLast 12Mto Jun 2026FY26Mar 2026
5-step DuPont — ROE = tax burden × interest burden × EBIT margin × turnover × leverage
0.68×0.67×
0.95×1.16×
12.7%13.0%
0.46×0.46×
1.74×1.74×
6.5%8.1%
8.1%8.1%
Open the chart

From the company's filings with NSE and BSE (Ind-AS), consolidated. For information only, not investment advice.

FISCHER₹25.93

Fischer Medical Ventures Limited

· Pharma & Health
₹ CrorePeersTARSONSLAXMIDENTLFABTECHGKBMcap ₹1,697 Cr
ProfitabilityGrowthCreditLiquidityWorking CapitalYield AnalysisDuPont
Ratios — % unless marked ×
12 Months Ending
FY26
31/03/2026
Last 12M
30/06/2026
5-Step DuPont — ROE = Tax Burden × Interest Burden × EBIT Margin × Turnover × Leverage
Tax Burden (Net Income/Pretax) ×0.670.68
Interest Burden (Pretax/EBIT) ×1.160.95
EBIT Margin %13.0012.67
Asset Turnover ×0.460.46
Financial Leverage (Assets/Equity) ×1.741.74
ROE (5-step product, year-end total equity) %8.066.51
ROE (owners' profit / average owners' equity) %8.078.07
No consensus estimates → no Est columns. Click any row to chart it.
« ‹ › »Latest: FY26 · ConsolidatedFA Financial Analysis · alphave
Data & compliance. Descriptive financial information from official NSE/BSE filings — for information and education only, not investment advice, a recommendation, or a valuation. Standalone = parent entity; consolidated includes subsidiaries. Historical multiples pair each fiscal year's filed figures with that FY-end market close; the Current column uses the last close with the latest filed annuals. Figures are cross-verified via accounting identities and NSE×BSE agreement — XBRL cross-verified ✓ 95%.